Revumenib

N/A

Report date: 2026/05/06 20:02:28
NMEFirst In Class

Base Information

Drug NameRevumenib
Drug Alias NameRevuforjSNDX-5613SNDX-50613
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMenin inhibitorsmenin-KMT2A interaction inhibitors
TargetsMenin
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsColorectal Neoplasms +[8] 
Global Approved IndicationsLeukemia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/11/15
Country/TerritoryCanadaUnited StatesPuerto Rico +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesVitae Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesStichting Hemato-Oncologie Voor Volwassenen Nederland (Hovon)National Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[7] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic NeoplasmsColorectal Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG